1. New primary malignant tumors.
2. Promotion of BRAF wild-type tumor growth.
3. Cardiomyopathy.
4. Hepatotoxicity.
5. Bleeding.
6. Uveitis.
7. QT interval prolongation.
8. Embryo-fetal toxicity.
9. Risks of BRAFTOVI monotherapy.
10. Risks of combination therapy.
FDA,2025.03